Trial Profile
Autologous Endothelial Progenitor Cell Therapy for Reversal of Liver Cirrhosis
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 04 Jan 2024
Price :
$35
*
At a glance
- Drugs Filgrastim (Primary)
- Indications Liver cirrhosis
- Focus Therapeutic Use
- 14 Jan 2021 Planned End Date changed from 31 Mar 2021 to 31 Dec 2023.
- 14 Jan 2021 Planned primary completion date changed from 31 Mar 2020 to 31 Dec 2022.
- 17 Apr 2017 New trial record